The CHRDL2 (Chordin-like 2) antibody is a tool used to study the CHRDL2 protein, a member of the Chordin family of secreted extracellular proteins. CHRDL2 functions as a bone morphogenetic protein (BMP) antagonist by binding to BMP ligands (e.g., BMP4. BMP2) and inhibiting their interaction with receptors, thereby modulating BMP signaling pathways. This pathway is critical in embryonic development, tissue homeostasis, and diseases such as cancer and fibrosis. CHRDL2 is expressed in various tissues, including the brain, heart, and skeletal muscle, and has been implicated in neural crest cell differentiation, angiogenesis, and tumor suppression.
Antibodies targeting CHRDL2 enable researchers to investigate its expression patterns, localization, and regulatory roles in both physiological and pathological contexts. For example, studies using CHRDL2 antibodies have revealed its upregulated expression in certain cancers, suggesting potential roles as a biomarker or therapeutic target. These antibodies are widely applied in techniques like Western blotting, immunohistochemistry, and immunofluorescence to visualize protein distribution and quantify expression levels in cell lines, animal models, or clinical samples. Recent research also explores CHRDL2's interaction with other signaling molecules (e.g., VEGF) in modulating vascular development. However, challenges remain in standardizing antibody specificity across experimental models, necessitating rigorous validation to ensure reliable data. Overall, CHRDL2 antibodies are vital for unraveling the protein's biological significance and translational potential.